All companies
Visit website
CANINE BIOLOGICS
OperatingCanine Life Sciences Inc.
Founded 2019
Our 2021 expansion brings breakthrough nutrition to more dogs with cancer
Post-money valuation ⓘ
$6.2M
As of Apr 2022 · from Canine Biologics Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$96,712
Across 2 rounds since 2021
Latest share price
$0.81
Canine Biologics Common Stock 1 offering price
Financials
FY2019–FY2022 · from SEC filings · hover any figure for its source$0
−$10K
2019
$6K
−$354K
2020
$6K
−$354K
2021
$49K
−$449K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
FY2021
FY2022
Income statement
Revenue
$0
$5,823
$5,823
$49,391
Cost of goods sold
$0
$5,650
$5,650
$72,559
Gross margin
—
3%
3%
-47%
Net income
-$10,497
-$353,517
-$353,517
-$449,310
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$119,551
$98,886
$98,886
$24,684
Accounts receivable
$0
$25,894
$25,894
$11,110
Total assets
$146,911
$403,282
$404,133
$159,970
Short-term debt
$8,409
$33,296
$19,100
$66,000
Long-term debt
$0
$0
$0
$0
Total liabilities
$8,409
$33,296
$19,100
$66,000
Other
Headcount
—
5
—
5
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$6.5M
Valuation cap
$6.2M
post-money
CANINE BIOLOGICS SAFE 1
Canine Biologics Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $39.1K / $477.5KPost-money $6.2M
Raised $57.6K / $1.1MInvestors 26Valuation cap $6.5M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 1 of 5 annual reports (FY2021–FY2025)
26 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001857342Share price $0.81
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.